In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 lg/kg once daily i.v.) pre-and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1-4 (58 vs 94%, Po0.001), 3-4 (13 vs 43%, Po0.001) and the median duration of OM (4 vs 9 days, Po0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%, Po0.001), opioid analgesics (24 vs 64%, Po0.001) and total parenteral nutrition (11 vs 45%, Po0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (P ¼ 0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.
Introduction
Oral mucositis (OM) may occur in up to 100% of patients undergoing high-dose chemo-/radiotherapy followed by hematopoietic stem cell transplant (HSCT). It results from the direct toxic effect of therapy on mucosa cells, but the mechanisms of mucositis seem to be more complex. [1] [2] [3] The appearance of OM is often considered to be linked to chemo-/radiotherapy-induced neutropenia, which predisposes patients to viral, bacterial and fungal infections. These infections could aggravate severity and prolong the duration of OM. 2 The risk factors for OM have not been well established, although some chemo-/radiotherapy regimen protocols make out that patients are at high risk because of particular mucotoxic agents administered: 5-fluorouracil, MTX, doxorubicin, etoposide (VP), melphalan (Mel), Ara-C and Cy. 1, 4 The clinical appearance of OM may range from mild discomfort to painful erythema, edema and ulcerations, which markedly interfere with the patient's quality of life. It also increases the risk of systemic infections and mortality of immunocompromised patients. 5 Moreover, OM may prolong hospitalization, increase the use of antibiotics and other anti-infections agents, analgesics, total parenteral nutrition (TPN), and thus have significant economic costs. 6, 7 Currently, there are no universal protocols that have been accepted as a standard to prevent and treat OM in the transplant setting. Research is proceeding on several new fronts, including cytokines and growth factors. [8] [9] [10] Palifermin, recombinant human-keratinocyte growth factor 1, discovered in 1989, 11 acts specifically by keratinocyte growth factor 1 receptor on epithelial cells, so it should be safe in hematological diseases and can play a role in the protection and regeneration of oral and gastrointestinal mucosa. [12] [13] [14] [15] In this multicenter study, we assessed the ability of palifermin to reduce the incidence, duration and severity of OM induced by high-dose chemo-/radiotherapy followed by HSCT in patients with hematological diseases. We also evaluated the requirement for analgesics and TPN administered because of OM, incidence of febrile neutropenia and severe infections. Moreover, we assessed the influence of palifermin on hematopoietic recovery, on the incidence of acute GvHD (aGvHD) and on the length of hospitalization after HSCT.
Patients' characteristics and methods
The patients enrolled in this study had a Karnofsky performance status score of at least 80 and underwent first autologous or allogeneic HSCT. They were transplanted because of malignant and non-malignant hematological diseases in 11 bone marrow transplant centers in Poland ( Table 1) . The study was planned as a single arm trial with a retrospective group of control patients selected by each center. Each of the reporting centers submitted an equal number of patients to the palifermin and control groups. The data were collected and analyzed by the principal investigator. The study was approved by the principal institutional review boards. There was no funding or other involvement from the company for this trial.
The patients in both groups were similar in terms of sex, age, diagnosis, state of disease, type of transplant, conditioning regimens and risk for OM and aGvHD (Table 1 ), but they were not matched for the number of pretransplant courses of chemotherapy and previous radiation.
One hundred and six patients with hematological diseases were enrolled in the study. Fifty-three of them (50%) received palifermin (Kepivance; Amgen, Breda, The Netherlands) 60 mg/kg once daily i.v. for 3 consecutive days before and after conditioning therapy (total six doses) and were transplanted between June 2005 and March 2006. All of them signed written informed consent before administration of the study drug.
The control patients (n ¼ 53) received their conditioning therapy without the addition of palifermin therapy and were transplanted between December 2000 and December 2005.
Conditioning therapy, GvHD prophylaxis and supportive care Conditioning therapy, GvHD prophylaxis and supportive care were administered according to the standard practice in both groups. Most of the patients were given myeloablative regimens. Reduced-intensity conditioning was adopted in one patient with multiple myeloma in the palifermin group and in three patients with multiple myeloma, AML, myelodysplastic syndrome in the control group. Fractioned TBI and cytotoxic agents VP, Mel, Ara-C, Cy, Bu, Flu, BCNU, CCNU were applied as conditioning regimens presented in Table 1 .
All patients who underwent allogeneic transplantations were given GvHD prophylaxis with CsA/MTX (15 mg/m 2 i.v. on day þ 1 and 10 mg/m 2 on days þ 3, þ 6, þ 11) and CsA/MTX/thymoglobulin (ATG) in transplant from related and unrelated donors, respectively.
No T-depleted bone marrow or G-CSF-stimulated peripheral blood was the source of stem cells in the palifermin and control groups.
The prophylaxis of fungal, herpetic, Pneumocystis carinii infections with fluconazole, acyclovir and trimethoprim/ sulfamethoxazole, respectively, was administered at most centers. All patients after alloHSCT were screened twice weekly for CMV by PCR assay, and upon positive tests were given pre-emptive ganciclovir or foscarnet therapy, according to the standard schedule. Growth factors, filgrastim (Neupogen; Amgen) or lenograstim (Granocyte; Sanofi-Aventis, Paris, France), were given for 8.8 days (range: 2-20 days) in 18 patients in the palifermin group and for 11.2 days (range: 5-23 days) in 22 patients in the control group with a different schedule and dose at each center because of graft failure (failure to achieve ANC of 0.5 Â 10 9 /l for 3 consecutive days some time after myeloablation or ANC of 0.1 Â 10 9 /l on day 21 after HSCT) and/or febrile neutropenia, severe infections or as a standard procedure.
Definitions
In both groups, OM was assessed daily by selected experienced hematologists, from starting conditioning therapy to discharge from the hospital or until death, with the five-grade WHO (World Health Organization) oral toxicity scale. 16 Acute GvHD was diagnosed and graded weekly after HSCT by the same physicians based on clinical symptoms (physical examination) and with biopsies of affected organs in some cases, according to the established criteria. 17 Adverse events of palifermin were also assessed daily by the same physicians according to the common toxicity criteria.
Onset of OM indicated a first day of appearance of OM symptoms after HSCT.
Duration of OM was defined as the time of OM symptoms after HSCT or until death.
Severe infections followed a symptomatic course (bronchitis, pneumonia, urinary tract infections and sepsis) and were documented with positive tests for bacteria, viruses or fungi. Febrile neutropenia was diagnosed in patients with fever X38 1C on several occasions and ANCo0.5 Â 10 9 /l with or without severe infections following HSCT. Engraftment was confirmed by an ANC of more than 0.5 Â 10 9 /l and a peripheral platelet count of 420 Â 10 9 /l for at least 3 consecutive days without requiring transfusions.
The length of hospitalization was defined as the time from HSCT to discharge from the hospital or until death.
Statistical analyses
The baseline characteristics of the patients (age, diagnosis and conditioning regimens) were compared between the two groups using either Student's t-test or the w 2 test. The same tests were applied to compare the outcomes of interest between the groups (incidence of OM grades 0-4 and 3-4, incidence of analgesics, opioid analgesics, TPN requirement, febrile neutropenia, severe infections and aGvHD). Fisher's exact test and the w 2 trend test were applied for the analysis of the aGvHD data.
The Mann-Whitney test was used to compare the groups for the onset of OM, duration of OM and distribution of peripheral platelet count and ANC (engraftment), while Student's t-test was applied to compare the duration of TPN, analgesics and opioid analgesics usage and the length of hospitalization after HSCT.
Statistical significance was represented by two-tailed probability P-values, with values p0.05 considered statistically significant. SPSS, GRETL and TANAGRA software programs were used to perform the statistical analyses.
Results
A comparison of baseline characteristics showed no statistical differences between the treatment and control groups ( Table 1 ). The incidence of OM of WHO grades 1-4 was 58% in the palifermin group and 94% in the control group (Po0.001), while grades 3-4 was 13% in the palifermin group and 43% in the control group (Po0.001). The mean duration of any grade of OM was 4 days (range: 0-16 days) in the palifermin group and 9 days (range: 0-28 days) in the control group (Po0.001). Compared with controls, the palifermin group was characterized by statistically significant reductions in the incidence of use of analgesics-paracetamol, metamizol and ibuprofen (32 vs 75.5%; Po0.001), including opioid analgesics-tramadol, fentanyl, pethidine and morphinum (24 vs 64%; Po0.001) given orally, transdermal, parenteral and in the duration of analgesics usage (7.1 vs 12 days, P ¼ 0.009) administered because of OM. Moreover, we observed a significant reduction in the incidence of TPN usage (11 vs 45%; Po0.001).
There were no statistically significant differences observed between the groups with regard to the onset of any OM after HSCT (3.1 days in the palifermin group vs 3.5 days in the control group), duration of TPN and opioid analgesics usage, incidence of febrile neutropenia and severe infections. Moreover, palifermin did not appear to impair reconstitution of the hematopoietic system and did not statistically reduce the mean length of hospitalization significantly after HSCT: 24.5 days (range: 10-60 days) in the palifermin group vs 28 days (range: 10-83 days) in the control group.
In the observation of aGvHD, we did not find statistical differences in the incidence of any aGvHD in the palifermin group compared to the control group (25 vs 50%; P ¼ 0.14).
The gut, liver and skin aGvHD incidence was 8.3, 8.3, 12.5% in the palifermin group and 29.2, 37.5, 29.2% in the control group and gave P-values of 0.14, 0.036 and 0.29, respectively. If we added each of the affected organs together, then we got a distribution of 0, 1, 2, 3 organs affected of 18, 5, 1, 0 for the palifermin group and 12, 5, 3, 4 for the control group (P ¼ 0.016). So, aGvHD was less prevalent in the palifermin group ( Table 2) .
The similar significance of all analyzed variables was observed when we stratified the data according to the HSC source (autologous vs allogeneic) ( Table 3) .
Of note, six patients in the palifermin group and two patients in the control group had platelet levels that never fell below 20 Â 10 9 /l following HSCT. Four patients (7.5%) in the palifermin group died-5, 14, 25 and 52 days following HSCT because of severe infections (documented sepsis) before neutrophil and platelet recovery in two patients (AMLs after autologous and allogeneic HSCT unrelated), veno-occlusive liver disease according to the Seattle criteria in the third patient (myelodysplastic syndrome after allogeneic HSCT related) and fourth stage of the liver aGvHD resistant to several immunosuppressive agents in the fourth patient (CML after allogeneic HSCT related).
Toxicity and safety
Palifermin was generally well tolerated. Adverse events occurred in 34 (64.1%) patients when palifermin was administered in 27 (50.9%) and after the last dose in 15 (28.3%).
Adverse events, mainly rash, pruritus, erythema, generalized edema, taste alteration, mouth/tongue thickness and discoloration and proteinuria, were mild in 15 (28.3%) to moderate in 15 patients in severity and were transient (Table 4 ). In 4 (7.5%) patients, adverse events were clinically severe but not life-threatening. We observed third 
Table 3
Effect of palifermin on OM, fever, severe infections, engraftment and duration of hospitalization stratifying the data based on donor source (autologous vs allogeneic)
Variable
Autologous Allogeneic
Palifermin group (n ¼ 29)
Control group (n ¼ 29)
Pvalues
Palifermin group (n ¼ 24)
Control group (n ¼ 24)
Incidence of OM grades 1-4 (n (%))
13 ( grade of skin reactions: generalized edema, rash and erythema with persistent pruritus or pain. But in no case did they cause the discontinuation of palifermin.
Discussion
Oral mucositis is the most debilitating factor in the opinion of patients who underwent HSCT. 18 The experience with this treatment approach is still very limited, especially in allogeneic HSCT, but to date is very encouraging. The results of the preclinically and clinically performed tests with palifermin so far are promising in patients with hematological malignancies receiving HSCT, who are at particular high risk for OM.
It was confirmed, in other studies, that palifermin significantly reduced incidence, 19 severity [19] [20] [21] [22] and duration of OM 20 and the use of analgesics 20 and TPN 20,22 without negative influence on engraftment. 19, 22 The present study confirms that 60 mg/kg once daily (total six doses) of palifermin, a new antimucositis agent, can effectively reduce the incidence, severity and duration of OM in autologous and allogeneic HSCT. The percentage of palifermin recipients who received analgesics, opioid analgesics and TPN because of OM was also significantly lower compared to the control patients in both types of transplants.
There was no significant difference in the onset of any OM after the HSCT, incidence of febrile neutropenia and severe infections, the time to engraftment and length of hospitalization between groups in both types of transplants in our study, although some other tests confirmed significant reduction in the length of hospitalization of patients treated with palifermin. 22, 23 Moreover, it has been shown both in animal and human models that palifermin might preserve gastrointestinal mucosal barrier integrity. This was assessed by serum citrulline levels and some cytokines that increase substantially after intestinal mucosal barrier damage. 24, 25 Then palifermin activity might ameliorate the symptoms of gut GvHD. 25 As was presented in animal models, it could result either from epithelial protection and regeneration or decreased production of proinflammatory lymphocyte T-helper 1 cytokines responsible for aGvHD severity with concomitant increased production of anti-inflammatory lymphocyte T-helper 2 cytokines associated with reduced GvHD incidence and severity. 25 Our special interest concerned the influence of palifermin on the incidence of aGvHD. There were no statistical differences in the incidence of any aGvHD in the palifermin group compared to the control group, but when we analyzed the distribution of organs affected with aGvHD, we found that it was significantly less prevalent in the palifermin group. It was surprising that we observed a significant difference in the incidence of liver and not of skin and gut aGvHD between groups, and to our knowledge this is a new observation.
However, in spite of our findings, the activity of palifermin in this matter needs future insightful observation because of published controversies. 19, 26 In a randomized study, Blazar et al. 19 showed no significant effect on the incidence and severity of aGvHD in the patients conditioned with two regimens: Cy/TBI or Bu/Cy, who received only related donor grafts. Our patients were at higher risk of aGvHD because 30% of allogeneic HSCT in both groups were unrelated. Thus, our results could indicate that palifermin modifies GvHD.
Blazar et al. 19 cited some other authors and also quite precisely described the possible influence of palifermin on thymic epithelium and on immune recovery. Thymic function is necessary for the generation of T cells after HSCT. It was found that thymopoiesis is especially inhibited by chronic GvHD. 27, 28 We could suppose that palifermin as a GvHD protector could support thymopoiesis and immune recovery, but we did not measure thymic output and determine the factors that influence thymic function after HSCT. Moreover, our observations were too short and concerned only aGvHD. This process seems to be more complex and needs future studies.
The adverse events, transient and mild to moderate in severity, mostly concerned skin and oral epithelium, the sites of pharmacological action of palifermin. In four cases, we observed severe but no life-threatening skin reactions. Similar symptoms were observed by Spielberger et al. 20 in autologous HSCT and Blazar et al. 19 in allogeneic HSCT.
In summary, the results of clinical tests performed so far could place palifermin into a standard practice to prevent and treat OM in patients with hematological diseases undergoing HSCT. The key published study for palifermin efficacy was performed in patients receiving autologous HSCT 20 and the value of this study extended beyond being confirmatory, by specifically identifying and comparing the allogeneic group. The activity of palifermin has been demonstrated in TBI-based auto-and allografts, 19, 20 and this study involves both TBI and, in majority, non-TBI regimens.
Our results suggest that the use of palifermin reduces OM after both autologous and allogeneic HSCT and probably aGvHD, but the issue of true effect can only be resolved by a randomized controlled trial using a variety of the TBI-and non-TBI-conditioning regimens.
We plan to continue observing our patients additionally for relapse, survival and possible secondary epithelial tumors that could be induced by palifermin. 29 
Table 4
Frequency of adverse events observed during or after treatment with palifermin 
